Newsletter Issue 2, mailed in January 2019, was Wellbeing’s second public document and the first that could meaningfully look back on a full year of activity. The 2018 calendar had been the most public year in Wellbeing’s history to that point. Issue 1 had been mailed in February. The Jimmy Graham testimonial had been released in January. A Spring 2018 newsletter had followed in April. Issue 2 was Wellbeing’s opportunity to consolidate that year and to set out what 2019 looked like from the inside.
The leading feature in the issue was a long review of the osteoarthritis research literature. Osteoarthritis is among the most common chronic joint conditions, affecting tens of millions of people globally, and the research literature on regenerative approaches to it had grown significantly through the 2010s. The newsletter review walked carefully through what published studies were and were not saying about the role of secreted biological factors in joint biology, including the work of Kuroda and colleagues in 2015 and the broader review literature from authors like Maumus and colleagues. The piece was careful in its language. It did not claim that Wellbeing treats osteoarthritis. It walked through the published evidence about regenerative biology in joint contexts and discussed how that evidence had shaped thinking about cell-free preparation methods.
Issue 2 included a profile of Doug Baldwin, the two-time Pro Bowl wide receiver who had spent his career to that point with the Seattle Seahawks. Baldwin had agreed, alongside Graham, to discuss his experience with Wellbeing’s programme. The profile in Issue 2 was the first time Baldwin had been named publicly in connection with the work. He has remained named in our public communication since.
Max Lewinsohn, Wellbeing’s chairman, contributed a note that opened the issue. The note covered Lewinsohn’s perspective on the year ahead, the discipline Wellbeing operated under, and the importance of patient-by-patient observation as the slow but reliable way of understanding what the programme was actually achieving. Lewinsohn’s background spans finance, strategy, and a long-running involvement with the science.
The middle of the issue covered selected patient outcomes from 2018, anonymously in most cases, across a range of clinical contexts. As with Issue 1, the language was careful. The newsletter described what patients had observed in their own bodies, what specific clinicians involved had observed, and where appropriate, what laboratory or imaging data had captured. It did not make systemic claims. Wellbeing’s working position then, as now, was that the patient-by-patient observed record is what the programme stands on.
The closing pages of Issue 2 looked forward to 2019. Wellbeing’s research partnerships at the time included relationships with academic and clinical groups working on related questions. The closing note acknowledged that progress in the field would continue to be incremental and that Wellbeing’s commitment was to that pace rather than to anything faster.
Like Issue 1, Issue 2 is an archival document. The specific outcomes, the specific partnerships, and the specific scientific framings reflect 2018 to 2019 reality, not 2026 reality. The work has moved on. The voice of Wellbeing, on the other hand, has changed remarkably little. The deliberate, observational, patient-focused tone of these early newsletters is the same tone Wellbeing uses in its current communication.
Issue 2 is available on request as part of the public archive. The osteoarthritis review in particular remains a useful walkthrough of the research literature for general readers interested in how regenerative-medicine research has thought about chronic joint conditions.